Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer
- PMID: 25437714
- PMCID: PMC4316672
- DOI: 10.1097/AOG.0000000000000484
Detection of somatic TP53 mutations in tampons of patients with high-grade serous ovarian cancer
Abstract
Objective: To investigate whether tumor cells could be detected in the vagina of women with serous ovarian cancer through TP53 analysis of DNA samples collected by placement of a vaginal tampon.
Methods: Women undergoing surgery for a pelvic mass were identified in the gynecologic oncology clinic. They placed a vaginal tampon before surgery, which was removed in the operating room. Cells were isolated and DNA was extracted from both the cells trapped within the tampon and the primary tumor. In patients with serous carcinoma, the DNA was interrogated for the presence of TP53 mutations using a method capable of detecting rare mutant alleles in a mixture of mutant and wild-type DNA.
Results: Thirty-three patients were enrolled. Eight patients with advanced serous ovarian cancer were included for analysis. Three had a prior tubal ligation. TP53 mutations were identified in all eight tumor samples. Analysis of the DNA from the tampons revealed mutations in three of the five patients with intact tubes (sensitivity 60%) and in none of the three patients with tubal ligation. In all three participants with mutation detected in the tampon specimen, the tumor and the vaginal DNA harbored the exact same TP53 mutation. The fraction of DNA derived from exfoliated tumor cells ranged from 0.01% to 0.07%.
Conclusion: In this pilot study, DNA derived from tumor was detected in the vaginas of 60% of patients with ovarian cancer with intact fallopian tubes. With further development, this approach may hold promise for the early detection of this deadly disease.
Conflict of interest statement
Comment in
-
Can molecular diagnostics usher in a new era for screening, diagnosis, and treatment of ovarian cancer?Obstet Gynecol. 2014 Nov;124(5):870-872. doi: 10.1097/AOG.0000000000000534. Obstet Gynecol. 2014. PMID: 25437712 No abstract available.
Similar articles
-
Prospective study of the efficacy and utility of TP53 mutations in circulating tumor DNA as a non-invasive biomarker of treatment response monitoring in patients with high-grade serous ovarian carcinoma.J Gynecol Oncol. 2019 May;30(3):e32. doi: 10.3802/jgo.2019.30.e32. J Gynecol Oncol. 2019. PMID: 30887755 Free PMC article.
-
Characterization of TP53 mutations in Pap test DNA of women with and without serous ovarian carcinoma.Gynecol Oncol. 2020 Feb;156(2):407-414. doi: 10.1016/j.ygyno.2019.11.124. Epub 2019 Dec 12. Gynecol Oncol. 2020. PMID: 31839337 Free PMC article.
-
Targeted Genomic Sequencing Reveals Novel TP53 In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.Anticancer Res. 2019 Jun;39(6):2883-2889. doi: 10.21873/anticanres.13417. Anticancer Res. 2019. PMID: 31177126
-
The fallopian tube, "precursor escape" and narrowing the knowledge gap to the origins of high-grade serous carcinoma.Gynecol Oncol. 2019 Feb;152(2):426-433. doi: 10.1016/j.ygyno.2018.11.033. Epub 2018 Nov 30. Gynecol Oncol. 2019. PMID: 30503267 Review.
-
A Comprehensive Review of Ovarian Serous Carcinoma.Adv Anat Pathol. 2019 Sep;26(5):329-339. doi: 10.1097/PAP.0000000000000243. Adv Anat Pathol. 2019. PMID: 31368906 Free PMC article. Review.
Cited by
-
Uterine washings as a novel method for early detection of ovarian cancer: Trials and tribulations.Gynecol Oncol Rep. 2024 Feb 3;51:101330. doi: 10.1016/j.gore.2024.101330. eCollection 2024 Feb. Gynecol Oncol Rep. 2024. PMID: 38356691 Free PMC article.
-
Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study.Int J Gynecol Cancer. 2018 Nov;28(9):1692-1698. doi: 10.1097/IGC.0000000000001361. Int J Gynecol Cancer. 2018. PMID: 30376484 Free PMC article.
-
Screening and Prevention for High-Grade Serous Carcinoma of the Ovary Based on Carcinogenesis-Fallopian Tube- and Ovarian-Derived Tumors and Incessant Retrograde Bleeding.Diagnostics (Basel). 2020 Feb 22;10(2):120. doi: 10.3390/diagnostics10020120. Diagnostics (Basel). 2020. PMID: 32098383 Free PMC article. Review.
-
Early Detection of Ovarian Cancer.Hematol Oncol Clin North Am. 2018 Dec;32(6):903-914. doi: 10.1016/j.hoc.2018.07.003. Epub 2018 Sep 28. Hematol Oncol Clin North Am. 2018. PMID: 30390764 Free PMC article. Review.
-
Current and Emerging Methods for Ovarian Cancer Screening and Diagnostics: A Comprehensive Review.Cancers (Basel). 2022 Jun 11;14(12):2885. doi: 10.3390/cancers14122885. Cancers (Basel). 2022. PMID: 35740550 Free PMC article. Review.
References
-
- Kindelberger DW, Lee Y, Miron A, Hirsch MS, Feltmate C, Medeiros F, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007 Feb;31(2):161–169. PubMed PMID: 17255760. Epub 2007/01/27. eng. - PubMed
-
- Piek JM, van Diest PJ, Zweemer RP, Jansen JW, Poort-Keesom RJ, Menko FH, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001 Nov;195(4):451–456. PubMed PMID: 11745677. Epub 2001/12/18. eng. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous